3710 Division of Dermatology, Department of Medicine, McMaster University, Hamilton, ON, Canada.
Dermatrials Research Inc. & Venderm Innovations in Psoriasis, Hamilton, ON, Canada.
J Cutan Med Surg. 2022 May-Jun;26(3):267-273. doi: 10.1177/12034754221078203. Epub 2022 Feb 8.
Certolizumab pegol (CZP) is a TNF-ɑ inhibitor used to treat moderate-to-severe plaque psoriasis (PsO) in adult patients, including women of childbearing potential (WOCBP) and patients with psoriatic arthritis (PsA). There are currently limited real-world data on CZP for treatment of PsO.
To examine the use of CZP for treatment of PsO in clinical practice at two dermatology clinics in Canada.
We conducted a retrospective chart analysis of 59 patients with moderate-to-severe psoriasis receiving CZP. Clinical efficacy was measured using the Psoriasis Area and Severity Index (PASI), Body Surface Area (BSA), and Physician Global Assessment (PGA). Drug survival was analyzed using Kaplan-Meier plots.
Of the 59 patients, 36 (61%) were female, of whom 23 (63.9%) were WOCBP. Twenty-three (39.0%) patients received CZP as their first biologic treatment. The main reasons for choosing CZP were its efficacy in both PsO and PsA, and for WOCBP due to little or no cross-placental transfer. Improvement of symptoms was observed after 3 months of treatment and was maintained for the 12-month analysis period. After 12 months of treatment, the patients' mean PASI score decreased from 13.0 (±5.8) at baseline to 2.3 (±4.3), mean BSA score from 13.1% (±6.7%) to 1.7% (±2.6%), and mean PGA score from 3.0 (±0.6) to 0.8 (±0.6). Overall CZP drug survival rate was 76.3% at 12 months, with no difference between biologic-naive and biologic-experienced patients.
CZP was effective and well tolerated in this cohort of patients with moderate-to-severe PsO in a real-world setting.
培塞利珠单抗（CZP）是一种 TNF-α抑制剂，用于治疗成人中重度斑块状银屑病（PsO），包括生育能力的女性（WOCBP）和患有银屑病关节炎（PsA）的患者。目前，关于 CZP 治疗 PsO 的真实世界数据有限。
在加拿大的两家皮肤科诊所检查 CZP 治疗 PsO 的临床应用。
我们对 59 名接受 CZP 治疗的中重度银屑病患者进行了回顾性图表分析。使用银屑病面积和严重程度指数（PASI）、体表面积（BSA）和医生总体评估（PGA）来衡量临床疗效。使用 Kaplan-Meier 图分析药物生存率。
在 59 名患者中，有 36 名（61%）为女性，其中 23 名（63.9%）为 WOCBP。23 名（39.0%）患者接受 CZP 作为他们的第一种生物制剂治疗。选择 CZP 的主要原因是其在 PsO 和 PsA 中的疗效，以及对于 WOCBP，因为几乎没有或没有胎盘转移。治疗 3 个月后观察到症状改善，并在 12 个月的分析期间保持。治疗 12 个月后，患者的平均 PASI 评分从基线时的 13.0（±5.8）降至 2.3（±4.3），平均 BSA 评分从 13.1%（±6.7%）降至 1.7%（±2.6%），平均 PGA 评分从 3.0（±0.6）降至 0.8（±0.6）。在 12 个月时，总体 CZP 药物生存率为 76.3%，生物制剂初治和生物制剂经验患者之间无差异。
在现实环境中，CZP 对该队列中度至重度 PsO 患者有效且耐受性良好。
